Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Published On Jan 24, 2025, 9:47 AM

Novo Nordisk's stock surged over 8% following positive Phase I results for its weight-loss drug, amycretin, which showed potential for up to 22% weight loss in early trials involving 125 participants. The drug operates similarly to existing treatments like Wegovy and Ozempic but incorporates an additional hormone, aiming to curb hunger more effectively. Despite the enthusiastic early results, concerns about gastrointestinal side effects and the need for larger Phase III trials remain significant. Overall, analysts believe these findings could reinvigorate interest in Novo's obesity treatment pipeline after a period of underperformance.